L26/O-160 Clinical relevance of high-level mosaicism after PGT-A: mosaic segmental aneuploidies drive unexpected live birth outcomes
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.158 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von F. Spinella und 9 weiteren Autor:innen.
Abstract (Originalsprache)
Study question To evaluate implantation, pregnancy and live birth outcomes following transfer of high-degree mosaic embryos (≥50%) and to identify chromosomal patterns associated with reproductive success. Summary answer High-degree mosaic embryos achieved ongoing pregnancy and live birth in approximately 24%, with segmental mosaics showing superior success (34%), indicating chromosome-specific patterns modulate reproductive potential. What is known already In recent years, the clinical relevance of embryonic mosaicism detected by PGT-A has been increasingly questioned. A growing body of opinion suggests abandoning mosaic reporting, classifying embryos simply as euploid (<50% mosaicism) or aneuploid (≥50%), with the latter excluded from transfer. However, robust outcome data on high-degree mosaic embryos remain limited, underscoring the importance of the International Registry of Mosaic Embryos (IRMET), which has collected thousands of real-world clinical outcomes from multiple IVF centers worldwide, providing an unprecedented evidence base to refine risk stratification and guide clinical decision-making. Study design, size, duration This retrospective study analyzed 4,200 mosaic embryos reported to IRMET between 2017 and 2025, collected from 22 IVF centers. Mosaic embryos were stratified according to degree of mosaicism and aneuploidy type (segmental versus whole-chromosome). Implantation, clinical pregnancy, and live birth outcomes were evaluated. Statistical analyses explored associations between mosaicism level, chromosomal pattern, and reproductive outcome, aiming to clarify the clinical potential of different mosaic profiles. Participants/materials, setting, methods All embryos were cultured to the blastocyst stage, with trophectoderm biopsy performed on Day 5 or on Day 6/7 for slow-developing embryos. Preimplantation genetic testing was conducted using high-resolution next-generation sequencing (NGS). TE biopsies were classified as mosaic when 20–80% abnormal cells were detected and further stratified by mosaicism level (<50% vs ≥ 50%). Clinical outcomes were compared across mosaic subgroups using chi-square statistical analyses. Main results and the role of chance Among 4,200, 969 embryos showed a high level of mosaicism (≥50%) and were included in the primary analysis. Despite being classified as high-degree mosaic, approximately 24% of transferred embryos resulted in ongoing pregnancies and healthy live births. Notably, embryos with segmental mosaic aneuploidies showed the highest reproductive potential, achieving a live birth rate of 34%, significantly higher than embryos with whole-chromosome mosaicism (19%). Successful outcomes were observed across multiple chromosomes and specific structural alterations, suggesting that not all high-degree mosaic profiles carry equivalent biological or clinical risk. Limitations, reasons for caution Retrospective design and IVF center variability may limit generalizability. While findings suggest key embryo selection factors, prospective studies are needed for validation. Standardizing PGT-A reporting could improve transfer decision-making, ensuring more precise clinical applications and minimizing risks associated with mosaic embryo transfers in reproductive medicine. Wider implications of the findings IRMET data demonstrate that high-degree mosaic embryos are not uniformly non-viable and can result in healthy live births, particularly when segmental aneuploidies are involved. These findings support continued reporting of mosaicism after PGT-A and advocate for a more nuanced, biology-driven approach to embryo selection and clinical counseling. Trial registration number No
Zitieren
APA
Spinella, F., Madjunkova, S., Besser, A., Zouves, C., Madjunkov, M., Greco, E., Grifo, J., Cheng, E., Cetinkaya, M., & Viotti, M. (2026). L26/O-160 Clinical relevance of high-level mosaicism after PGT-A: mosaic segmental aneuploidies drive unexpected live birth outcomes. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.158
Vancouver
Spinella F, Madjunkova S, Besser A, Zouves C, Madjunkov M, Greco E, et al. L26/O-160 Clinical relevance of high-level mosaicism after PGT-A: mosaic segmental aneuploidies drive unexpected live birth outcomes. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.158
BibTeX
@article{Spinella2026,
author = {Spinella, F. and Madjunkova, S. and Besser, A. and Zouves, C. and Madjunkov, M. and Greco, E. and Grifo, J. and Cheng, E.-H. and Cetinkaya, M. and Viotti, M.},
title = {L26/O-160 Clinical relevance of high-level mosaicism after PGT-A: mosaic segmental aneuploidies drive unexpected live birth outcomes},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.158}
}
EUVIMED